Wall Street Analysts Predict a 57.17% Upside in Keros Therapeutics (KROS): Here's What You Should KnowZacks Investment Research • Thursday
Keros Therapeutics Announces Additional $5 Million Share Repurchase AuthorizationGlobeNewsWire • Monday
Down 21% in 4 Weeks, Here's Why Keros Therapeutics (KROS) Looks Ripe for a TurnaroundZacks Investment Research • 11/10/26
Keros Therapeutics, Inc. (KROS) Q3 Earnings and Revenues Surpass EstimatesZacks Investment Research • 11/05/26
Keros Therapeutics to Receive Additional Development Milestone Payment from Partner TakedaGlobeNewsWire • 09/29/26
Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMDGlobeNewsWire • 09/28/26
Why Is Keros Therapeutics (KROS) Up 8% Since Last Earnings Report?Zacks Investment Research • 09/02/26
Should You Buy KROS Stock as Pipeline Promise Meets Revenue Risk?Zacks Investment Research • 08/24/26
KROS $20M Takeda Milestone Adds Cash but Revenue Visibility Stays WeakZacks Investment Research • 08/24/26
KROS Q2 Earnings Miss as Revenues Fall to Zero, Pipeline in FocusZacks Investment Research • 08/04/26
Keros Therapeutics to Receive Development Milestone Payment from Partner TakedaGlobeNewsWire • 07/30/26
Keros Therapeutics, Inc. (KROS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeeking Alpha • 06/08/26
Keros Therapeutics Announces Participation at Goldman Sachs 47th Annual Global Healthcare ConferenceGlobeNewsWire • 06/01/26